Mary M. Rozenman
2015
In 2015, Mary M. Rozenman earned a total compensation of $1.1M as Senior Vice President, Corporate Development and Strategy at Aimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $90,700 |
|---|---|
| Option Awards | $719,157 |
| Salary | $252,083 |
| Total | $1,061,940 |
Rozenman received $719.2K in option awards, accounting for 68% of the total pay in 2015.
Rozenman also received $90.7K in non-equity incentive plan and $252.1K in salary.
Rankings
In 2015, Mary M. Rozenman's compensation ranked 7,651st out of 13,638 executives tracked by ExecPay. In other words, Rozenman earned more than 43.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,651 out of 13,638 | 44th |
Division Manufacturing | 2,898 out of 5,187 | 44th |
Major group Chemicals And Allied Products | 1,049 out of 1,857 | 44th |
Industry group Drugs | 846 out of 1,531 | 45th |
Industry Pharmaceutical Preparations | 663 out of 1,179 | 44th |
Source: SEC filing on April 12, 2016.
Rozenman's colleagues
We found two more compensation records of executives who worked with Mary M. Rozenman at Aimmune Therapeutics in 2015.